The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Miller Michael Patrick since 2015.
This trader's CIK number is 1236514.
At the time of last reporting, Miller Michael Patrick was the Director of Puma Biotechnology, Inc.. (stock ticker symbol PBYI).
Also see all insider trading activities at Puma Biotechnology, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | PBYI | 0 | $0 | 20,000 | $97,220 | 0 | $0 |
| 2024 | PBYI | 0 | $0 | 23,358 | $81,472 | 0 | $0 |
| 2023 | PBYI | 0 | $0 | 38,500 | $117,429 | 0 | $0 |
| 2022 | PBYI | 0 | $0 | 50,653 | $160,602 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | JAZZ | 0 | $0 | 4,500 | $586,695 | 0 | $0 |
| 2019 | JAZZ | 0 | $0 | 1,500 | $223,680 | 0 | $0 |
| 2018 | JAZZ | 0 | $0 | 2,200 | $353,248 | 0 | $0 |
| 2017 | JAZZ | 0 | $0 | 1,400 | $199,105 | 0 | $0 |
| 2016 | JAZZ | 0 | $0 | 1,500 | $189,052 | 0 | $0 |
| 2015 | JAZZ | 0 | $0 | 400 | $54,810 | 0 | $0 |
1. Puma Biotechnology, Inc. (PBYI)
2. Jazz Pharmaceuticals Plc (JAZZ)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-11-11 | PBYI | Sale | 20,000 | 4.86 | 97,220 |
| 2024-08-12 | PBYI | Sale | 23,358 | 3.49 | 81,472 |
| 2023-11-07 | PBYI | Sale | 25,000 | 2.83 | 70,800 |
| 2023-06-13 | PBYI | Sale | 13,500 | 3.45 | 46,629 |
| 2022-08-09 | PBYI | Sale | 25,000 | 3.55 | 88,800 |
| 2022-03-16 | PBYI | Sale | 25,653 | 2.80 | 71,802 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-03-12 | JAZZ | Sale | 1,500 | 102.17 | 153,255 |
| 2020-02-13 | JAZZ | Sale | 1,500 | 142.18 | 213,270 |
| 2020-01-13 | JAZZ | Sale | 1,500 | 146.78 | 220,170 |
| 2019-12-09 | JAZZ | Sale | 1,500 | 149.12 | 223,680 |
| 2018-11-13 | JAZZ | Sale | 200 | 149.27 | 29,854 |
| 2018-10-12 | JAZZ | Sale | 200 | 158.46 | 31,692 |
| 2018-09-14 | JAZZ | Sale | 200 | 165.20 | 33,040 |
| 2018-08-14 | JAZZ | Sale | 200 | 175.70 | 35,140 |
| 2018-07-13 | JAZZ | Sale | 200 | 179.15 | 35,830 |
| 2018-06-14 | JAZZ | Sale | 200 | 176.53 | 35,306 |
| 2018-05-14 | JAZZ | Sale | 200 | 164.68 | 32,936 |
| 2018-04-13 | JAZZ | Sale | 200 | 157.49 | 31,498 |
| 2018-03-14 | JAZZ | Sale | 200 | 151.12 | 30,224 |
| 2018-02-14 | JAZZ | Sale | 200 | 139.99 | 27,998 |
| 2018-01-12 | JAZZ | Sale | 200 | 148.65 | 29,730 |
| 2017-12-11 | JAZZ | Sale | 200 | 139.15 | 27,830 |
| 2017-08-15 | JAZZ | Sale | 200 | 144.38 | 28,876 |
| 2017-07-17 | JAZZ | Sale | 200 | 154.97 | 30,994 |
| 2017-06-15 | JAZZ | Sale | 200 | 150.65 | 30,130 |
| 2017-04-17 | JAZZ | Sale | 200 | 152.56 | 30,512 |
| 2017-03-15 | JAZZ | Sale | 200 | 137.89 | 27,577 |
| 2017-01-17 | JAZZ | Sale | 200 | 115.93 | 23,186 |
| 2016-12-15 | JAZZ | Sale | 200 | 103.09 | 20,618 |
| 2016-11-15 | JAZZ | Sale | 200 | 112.19 | 22,438 |
| 2016-10-17 | JAZZ | Sale | 200 | 118.16 | 23,632 |
| 2016-09-19 | JAZZ | Sale | 200 | 126.17 | 25,234 |
| 2016-08-15 | JAZZ | Sale | 100 | 136.45 | 13,644 |
| 2016-07-15 | JAZZ | Sale | 100 | 142.43 | 14,243 |
| 2016-06-15 | JAZZ | Sale | 100 | 149.64 | 14,963 |
| 2016-05-16 | JAZZ | Sale | 100 | 145.20 | 14,519 |
| 2016-04-15 | JAZZ | Sale | 100 | 145.79 | 14,579 |
| 2016-03-15 | JAZZ | Sale | 100 | 129.17 | 12,916 |
| 2016-01-15 | JAZZ | Sale | 100 | 122.66 | 12,266 |
| 2015-12-15 | JAZZ | Sale | 100 | 136.99 | 13,699 |
| 2015-11-16 | JAZZ | Sale | 100 | 134.03 | 13,403 |
| 2015-10-15 | JAZZ | Sale | 100 | 131.86 | 13,186 |
| 2015-09-25 | JAZZ | Sale | 100 | 145.23 | 14,522 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Miller Michael Patrick (Director of Puma Biotechnology, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.